This paper is in the following e-collection/theme issue:

Infoveillance and Social Listening (300) JMIR Theme Issue: COVID-19 Special Issue (2543) Web-based and Mobile Health Interventions (3915) Data Sources and Open Data for Infodemiology (24) COVID-19 Vaccination (175) Pharmacovigilance (168) Vaccination Sentiment and Anti-Vaccination Infodemiology (85) AI Language Models in Health Care (172) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (210)

Published on in Vol 4 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/53424, first published .
Application of a Language Model Tool for COVID-19 Vaccine Adverse Event Monitoring Using Web and Social Media Content: Algorithm Development and Validation Study

Application of a Language Model Tool for COVID-19 Vaccine Adverse Event Monitoring Using Web and Social Media Content: Algorithm Development and Validation Study

Application of a Language Model Tool for COVID-19 Vaccine Adverse Event Monitoring Using Web and Social Media Content: Algorithm Development and Validation Study

Authors of this article:

Chathuri Daluwatte1 Author Orcid Image ;   Alena Khromava2 Author Orcid Image ;   Yuning Chen1 Author Orcid Image ;   Laurence Serradell3 Author Orcid Image ;   Anne-Laure Chabanon4 Author Orcid Image ;   Anthony Chan-Ou-Teung5 Author Orcid Image ;   Cliona Molony1 Author Orcid Image ;   Juhaeri Juhaeri6 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics Author Video

Chathuri Daluwatte   1 , PhD ;   Alena Khromava   2 , MD, MPH ;   Yuning Chen   1 , MS, PhD ;   Laurence Serradell   3 , PhD ;   Anne-Laure Chabanon   4 , PharmD, PhD ;   Anthony Chan-Ou-Teung   5 , MS ;   Cliona Molony   1 , PhD ;   Juhaeri Juhaeri   6 , PhD

1 Digital Data, Sanofi, Cambridge, MA, United States

2 Epidemiology and Benefit-Risk Department, Sanofi, Toronto, ON, Canada

3 Epidemiology and Benefit-Risk Department, Sanofi, Lyon, France

4 Global Pharmacovigilance Department, Sanofi, Lyon, France

5 Digital Data, Sanofi, Lyon, France

6 Epidemiology and Benefit-Risk Department, Sanofi, Bridgewater, NJ, United States

Corresponding Author: